<DOC>
	<DOCNO>NCT00005060</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one chemotherapy drug surgery may kill tumor cell . It yet know chemotherapy follow surgery effective surgery follow chemotherapy stomach cancer . PURPOSE : This randomized phase III trial study surgery follow combination chemotherapy see well work compare combination chemotherapy follow surgery treating patient locally advanced stomach cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Surgery Treating Patients With Locally Advanced Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare , intention treat analysis , feasibility efficacy 4 course docetaxel , cisplatin , fluorouracil preoperative postoperative chemotherapy patient locally advance operable gastric carcinoma . - Evaluate predictive value biological molecular tumor parameter response chemotherapy , metastasis survival patient population . OUTLINE : This randomize , open label , multicenter study . Patients stratify accord study center , tumor site ( affect Z-line ( cardia carcinoma Siewart II III ) v rest stomach ) , nodal status ( positive v negative ) . Patients randomize either preoperative chemotherapy follow surgery ( arm I ) surgery follow postoperative chemotherapy ( arm II ) . - Arm I : Patients receive docetaxel IV 1 hour follow cisplatin IV 4 hour day 1 , fluorouracil IV continuously day 1-14 every 3 week . Patients evaluate 2 course patient progressive disease proceed immediate surgery . Otherwise , treatment continue total 4 course absence unacceptable toxicity disease progression . Between 3-5 week follow day 1 last course chemotherapy , patient undergo gastric resection . - Arm II : Patients undergo immediate gastric resection . Beginning 3-6 week surgery , patient receive 4 course docetaxel , cisplatin , fluorouracil arm I . Quality life assess first third course chemotherapy , surgery , 1 , 3 , 6 month . Patients follow every 3 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 240 patient ( 120 per arm ) accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locally advanced gastric carcinoma consider operable T34 , Nx , M0 OR Tx , N+ , M0 Lymph node consider positive sonography least 2 follow : Round Echopoor Sharp border At least 0.5 cm No distant metastasis , include peritoneal carcinomatosis CT scan peritoneal lavage mandatory PATIENT CHARACTERISTICS : Age : 18 75 Performance status : 02 Life expectancy : Greater 12 week Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST ALT great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Renal : Adequate renal function within limit allow treatment cisplatin Cardiovascular : No unstable cardiac disease require treatment No congestive heart failure angina pectoris even medically control No significant arrhythmias No myocardial infarction within past 6 month Ejection fraction great 50 % cardiac sonography MUGA scan Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy except basal cell carcinoma skin adequately treat carcinoma situ cervix No grade 2 great peripheral neuropathy origin ( e.g. , alcohol , diabetic ) No history anaphylaxis No serious concurrent illness medical condition would preclude study therapy No history significant neurologic psychiatric disorder ( e.g. , psychotic disorder , dementia , seizure ) PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy gastric carcinoma Chemotherapy : No concurrent chemotherapy gastric carcinoma Endocrine therapy : No concurrent endocrine therapy gastric carcinoma Radiotherapy : No concurrent radiotherapy gastric carcinoma Surgery : See Disease Characteristics Other : At least 30 day since prior treatment clinical trial No concurrent experimental drug No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
</DOC>